Cell calcification supressing proteins, and genes of the proteins

ABSTRACT

This invention provides cell-calcification inhibitory proteins as well as genes encoding the proteins. Based on the discovery of a novel isoform gene of the c-erg gene (herein referred to as “C-11 gene”) which is an erg gene derived from chickens, the nucleotide sequence of the gene has been determined, and then the expression of a protein encoded by such gene (herein referred to as “C-11 protein”) has been confirmed. Further, it has been discovered that when the c-erg or C-11 gene is introduced into osteoblasts, the calcification of the cells is inhibited.

BACKGROUND OF THE INVENTION

[0001] 1. Field of the Invention

[0002] This invention relates to cell-calcification inhibitory proteins as well as to genes encoding such proteins.

[0003] 2. Description of Related Art

[0004] Ets genes were first identified as oncogene of avian acute leukemia virus E26. Recently, the family of Ets related genes (Ets gene superfamily) has been found in a host ranging from human to Drosophila. It is believed that these genes are a transcriptional modulator which plays a basic, important role in the control of proliferation and differentiation of cells. In contrast, the biological functions of the Ets gene superfamily are hardly known.

SUMMARY OF THE INVENTION

[0005] Recently, it has been reported that the Ets related genes (erg) are specifically expressed at the sites of cartilage formation. This indicated the possibility of erg's being involved to some extent in skeleton formation at its initial stages. The present inventors, based on such findings, have accomplished the invention by introducing into osteoblasts, an erg gene derived from chickens (herein referred to as “chicken-erg gene” or “c-erg gene”) and by successfully elucidating the functions of the c-erg gene.

BRIEF DESCRIPTION OF THE DRAWINGS

[0006] This application contains at least one figure in color. Copies of a patent issuing from the application, which includes color figures, will be available from the United States Patent and Trademark Office upon request and payment of necessary fees.

[0007]FIG. 1 illustrates the nucleotide sequence for c-erg cDNA and the deduced amino acid sequence for c-erg protein, were the nucleotide sequence lacking the underlined portion of sequence in the figure corresponds to the C-11 gene nucleotide sequence according to this invention.

[0008]FIG. 2 illustrates the gene domain encoding the c-erg protein, where ETA, NRT, EDB, and CTA represent an erg/ets transcription domain, a transcription repressor domain, an erg/ets DNA-binding domain, and a carboxyl terminal transcription domain, respectively.

[0009]FIG. 3 illustrates an autoradiograph of the gel electrophoresis results showing RT-PCR amplified products obtained in Example 2-4, where a 473 bp band and a 392 bp band, correspond to c-erg and C-11, respectively.

[0010]FIG. 4 illustrates the results comparing DNA synthesizing abilities of Rcas (osteoblasts infected with RCAS only), c-erg-L14 (osteoblasts infected with a c-erg sense segment-introduced RCAS), and c-erg-L44 (osteoblasts infected with a c-erg antisense segment-introduced RCAS).

[0011]FIG. 5 illustrates the results comparing the DNA synthesizing abilities of Rcas (the osteoblasts infected with RCAS only) and C-11-L14 (osteoblasts infected with a C-11 sense segment-introduced RCAS).

[0012]FIG. 6 illustrates the results comparing alkaline phosphatase activities of Rcas (the osteoblasts infected with only RCAS), c-erg-L14 (the osteoblasts infected with the c-erg sense segment-introduced RCAS) and c-erg-L44 (the osteoblasts infected with the c-erg antisense segment-introduced RCAS).

[0013]FIG. 7 illustrates the results comparing the alkaline phosphatase activities of Rcas (the osteoblasts infected with RCAS only) and C-11-L14 (the osteoblasts infected with the C-11 sense segment-introduced RCAS).

[0014]FIG. 8 illustrates a photograph showing the results on deposition of calcified products in a culture system consisting of uninfected osteoblasts (the upper half) and the osteoblasts infected with RCAS only (the lower half) as measured by the Alizarin Red staining.

[0015]FIG. 9 illustrates a photograph showing the results on deposition of calcified products in a culture system consisting of the osteoblasts infected with c-erg-L14 RCAS (sense segment) (the upper half) and the osteoblasts infected with c-erg-L44 RCAS (antisense segment) (the lower half) as measured by the Alizarin Red staining.

[0016]FIG. 10 illustrate a photograph showing the results on deposition of calcified products in a culture system consisting of the osteoblasts infected with RCAS only, the osteoblasts infected with c-erg-L14 RCAS (sense segment), the osteoblasts infected with c-erg-L44 RCAS (antisense segment), and the osteoblasts infected with C-11-L14 RCAS (sense segment) as measured by the Alizarin Red staining.

[0017]FIG. 11 illustrates a photograph showing the results on deposition of calcified products within cell nuclei in a culture system consisting of the osteoblasts infected with RCAS only, the osteoblasts infected with c-erg-L14 RCAS (sense segment), the osteoblasts infected with c-erg-L44 RCAS (antisense segment), and the osteoblasts infected with C-11-L14 RCAS (sense segment) as measured by the von Kossa staining (the right two columns) in addition to those obtained by double-staining the cell nuclei of the respective osteoblasts with Alum-carmine (the left column).

DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] The present inventors have discovered a novel isoform gene of the c-erg gene (herein referred to as “C-11 gene” or “C11 gene”) which is an erg gene derived from chicken and determined its nucleotide sequence. Furthermore, the inventors have confirmed the expression of a protein encoded by such gene (herein referred to as C-11 protein or “C11 protein”).

[0019] Also, the inventors have discovered that when the c-erg or C-11 gene is introduced into osteoblasts, the calcification of the blasts (or cells) is inhibited.

[0020] More specifically, this invention provides a C-11 protein comprising a protein selected from the group consisting of:

[0021] (a) a protein comprising an amino acid sequence having SEQ ID NO. 2 (SEQUENCE LISTING), and

[0022] (b) a protein comprising an amino acid sequence that is derived from the amino acid sequence having SEQ ID NO. 2 by deletion, substitution or insertion of one or more amino acids, said protein having cell-calcification inhibitory activity.

[0023] Also, the invention provides a gene encoding the aforementioned protein.

[0024] Further, the invention provides a pharmaceutical composition comprising the aforementioned protein as well as provides a pharmaceutical composition intended for a cell-calcification inhibitor.

[0025] Also, the invention provides a cell-calcification inhibitor comprising a c-erg protein selected from the group consisting of:

[0026] (a) a protein comprising an amino acid sequence having SEQ ID NO. 4 (SEQUENCE LISTING); and

[0027] (b) a protein comprising an amino acid sequence that is derived from the amino acid sequence having SEQ ID NO. 4 by deletion, substitution or insertion of one or more amino acids, said protein having cell-calcification inhibitory activity.

[0028] Further, the invention provides an antibody to the C-11 protein as well as provides an antibody, characterized in that said antibody is a monoclonal antibody.

[0029] Still further, the invention provides a method for measuring the calcification of cells comprising the step of measuring the expression of a C-11 gene or a c-erg gene in the cells.

[0030] Also, the invention provides the aforementioned method wherein the expression of the gene is measured by the amount of C-11 mRNA expressed in the cells or the amount of c-erg mRNA expressed in the cells using a probe against a DNA sequence specific to the C-11 gene or to the c-erg gene.

[0031] Also, the invention provides the aforementioned method wherein the expression of the gene is measured by the amount of expression of the C-11 protein in the cells or the amount of expression of the c-erg protein in the cells.

[0032] Further, the invention provides the aforementioned method wherein the expression of the C-11 protein or the c-erg protein in the cells is measured by means of an antibody to the C-11 protein or to the c-erg protein.

[0033] Also, the invention provides a method for diagnosing such diseases as OPLL (Ossification of posterior longitudinal ligament) and osteoarthritis which cause pathologic calcification or ossification, said method comprising using the aforementioned method of measurement of the cell-calcification.

[0034] In addition, the invention provides a kit for measuring the calcification of cells, comprising either or both of an antibody to the C-11 protein and an antibody to the c-erg protein.

[0035] Further, the invention provides a method for screening a substance having cell-calcification inhibitory blocking activity, said method comprising using cells transformed with a gene encoding a protein selected from the group consisting of:

[0036] (a) a protein comprising an amino acid sequence having SEQ ID NO. 2 (SEQUENCE LISTING);

[0037] (b) a protein comprising an amino acid sequence that is derived from the amino acid sequence having SEQ ID NO. 2 by deletion, substitution or insertion of one or more amino acids, said protein having cell-calcification inhibitory activity;

[0038] (c) a protein comprising an amino acid sequence having SEQ ID NO. 4 (SEQUENCE LISTING); and

[0039] (d) a protein comprising an amino acid sequence that is derived from the amino acid sequence having SEQ ID NO. 4 by deletion, substitution or insertion of one or more amino acids, said protein having cell-calcification inhibitory activity.

[0040] Furthermore, the invention provides a pharmaceutical composition comprising an erg protein.

[0041] Also, the invention provides a pharmaceutical composition comprising an erg gene.

[0042] Further, the invention provides a pharmaceutical composition comprising the C-11 protein or the c-erg protein.

[0043] In addition, the invention provides a pharmaceutical composition comprising the C-11 gene or the c-erg gene.

[0044] Still further, the invention provides a pharmaceutical composition comprising a protein having a consensus amino acid sequence between the c-erg protein and the C-11 protein.

[0045] In the present specification and the accompanying drawings where abbreviations are used to describe bases and amino acids. The abbreviations according to the IUPAC-IUB rules or those ascertainable in the art to which the invention pertains are used as set forth in the following: Nucleic Acid DNA Deoxyribonucleic acid cDNA Complementary DNA RNA Ribonucleic acid mRNA Messenger RNA A Adenine C Cytosine G Guanine T Thymine

[0046] Isolation and Identification of C-11 Gene

[0047] The novel gene according to this invention is an isoform of the c-erg gene derived from chickens. As shown in FIG. 1, when compared with the nucleotide sequence for the c-erg gene, the novel gene has a nucleotide sequence lacking 81 nucleotides from nucleotide 655 to nucleotide 735 (See, SEQ ID NO. 1 in the Sequence Listing). The novel gene according to the invention (or C-11 gene) can be isolated from a variety of cells by a method ordinarily known in the art.

[0048] Specifically, total RNA is extracted from chicken embryos, 4-10 days old. After the RNA has been subjected to reverse transcription, the entire translational region of the c-erg gene and C-11 gene can be amplified by the PCR method.

[0049] Primers that can be used in PCR, for example, include the following C11B and C11C which amplify both c-erg and C-11 genes: C11B:5′- CACATTATGGCAAGCACTATTAAGG - 3′ C11C:5′- CACTTAGTAGTAGGTGCCAAGATGG - 3′ C11A:5′- ATCTTGATCACATTATGGCAAGC - 3′

[0050] When Primers C11B and C11C are each used, two bands, 1446 bp and 1355 bp, appear: the former band corresponds to the c-erg gene and the latter band to the C-11 gene, respectively. When Primers C11A and C11C are each used, two kinds of DNAs, 1454 bp (c-erg) and 1373 bp (C-11), can be amplified.

[0051] In either case, the RT-PCR conditions are as follows: 1 μg of total RNA is subjected to reverse transcription and subsequently to 30 cycles of amplification for one minute at 61° C., for two minutes at 72° C. and for 10 seconds at 95° C. employing 2 units of Tag polymerase to render the products detectable.

[0052] In addition, based on the determined nucleotide sequence as described above it is easy to prepare an oligonucleotide probe complementary to an appropriate partial nucleotide sequence thereof. Such probes may be used to enable detection of the C-11 gene by various techniques.

[0053] C-11 Protein

[0054] The C-11 protein which can be deduced from the nucleotide sequence for the C-11 gene has an amino acid sequence set forth in SEQ ID NO. 2 in the Sequence Listing.

[0055] The C-11 protein can also be expressed in suitable host cells by incorporating the C-11 gene into viral vectors such as adenovirus and chicken retrovirus. See Gene Transfer and Expression: A Laboratory Manual by Michael Kriegler, W.H. Freeman and Company, New York (1991), p29-56. Further, the amino acid sequence of the proteins thus obtained can be directly determined on a conventional amino acid sequencer.

[0056] Furthermore, it is possible to modify the sequence of the C-11 gene set forth as SEQ ID NO. 1 in the Sequence Listing by substitution, deletion or insertion of an arbitrary sequence in said sequence using, for example, site-directed mutagenesis. The site-directed mutagenesis can be repeated one to a few times to prepare C-11 protein variants in which one to a few amino acids are substituted, deleted or inserted as well as gene mutants encoding the variants. Such variants are within the scope of the invention insofar as they possess cell-calcification inhibitory activity.

[0057] Also, various methods known in the art may be used to detect the C-11 protein expressed within particular cells. Specifically, representative methods include immunostaining using an antibody to the C-11 protein or a partial protein thereof, a method for the detection of their localization by the use of a fluorescent antibody technique, and a method for measuring the amount of expression of the C-11 protein by means of a radioimmunoassay or ELISA technique on homogenated cells.

[0058] c-erg Protein

[0059] In a manner similar to that used for the C-11 protein, it is possible to express the c-erg protein set forth as SEQ ID NO. 4 in the Sequence Listing.

[0060] Further, variants of the c-erg protein or mutants of their genes can be prepared in a manner similar to that used for the C-11 protein or genes thereof, and can satisfactorily be utilized in this invention insofar as they possess cell-calcification inhibitory activity.

[0061] Antibody (Monoclonal Antibody) to C-11 Protein

[0062] An antibody to the C-11 protein according to the invention may be that which reacts against either the aforementioned entire C-11 protein or a partial oligopeptide thereof. In addition, it is possible to use an antibody conjugated with a suitable substance such as a protein which will impart particular properties to the antibody.

[0063] There is no limitation concerning immunological methods in which the aforementioned proteins etc., are used as antigens, and any immunological techniques ordinarily known in the art may be used. Following such methods, a serum containing polyclonal antibodies may be obtained. Further, particular fractions such as IgG can be obtained by purification through ammonium sulfate fractionation or on Protein A Sepharose.

[0064] Furthermore, it is also possible to prepare monoclonal antibodies by the cell fusion method.

[0065] Cell-Calcification Inhibitory Activity

[0066] “Cell-calcification inhibitory activity” caused by introduction of the C-11 gene or the c-erg gene according to the invention, into cells means the inhibition of calcification inductive ability by osteoblasts infected with viral vectors having the aforementioned genes cloned. In this invention the Alizarin Red method may preferably be used to measure the amount of deposition of calcified products which the cells have induced. Also, the von Kossa method (also known as the Alum-carmine method) permits easy discrimination.

[0067] Pharmaceutical Compositions and Methods for their Administration

[0068] The pharmaceutical compositions according to the invention are characterized by containing the erg protein, erg gene, C-11 protein, c-erg protein, C-11 gene or c-erg gene, each of which has the function to inhibit the calcification of cells as described above. Accordingly, by virtue of the cell-calcification inhibition, those compositions are capable of treating various diseases, more specifically those in which pathological calcification causes ossification such as OPLL and osteoarthritis.

[0069] The pharmaceutical compositions provided by the invention are those which contain the aforementioned erg protein, erg gene, C-11 protein, c-erg protein, C-11 gene or c-erg gene. Method for administration of those pharmaceutical compositions are not particularly limited, and conventional administration method are available for use. Specifically, these include local injection, subcutaneous injection and oral administration. In addition, intracellular microinjection or the like may be indicated.

[0070] More specifically, by introducing into the cells, the c-erg protein or the C-11 protein in its form bound to a suitable hormone or the like, or in its form as a fused protein, it is possible to have the c-erg or C-11 protein bound to receptors for the hormone, which allows the c-erg or C-11 protein together with the hormone to be taken up within the cells.

EXAMPLE 1

[0071] Isolation of C-11 Gene and c-erg Gene

[0072] Sterna were separated from chicken embryos, 18 days old and total RNA was then extracted. See, Iwamoto M. et al., Microscopy Research and Technique (1994) 28: 483-491. After the RNA thus obtained had been subjected to reverse transcription, amplification was allowed to proceed 30 cycles for one minute at 61° C., for two minutes at 72° C., and for 10 seconds at 95° C., respectively using PCR Primers (C11A and C11C, or C11B and C11C) which amplify the entire coding region for the c-erg gene. With either pair of the primers, two bands were obtained. Respective bands were cut out and DNA fragments were identified using a QiaexII gel extraction kit (Qiagen, Germany). These fragments were subcloned into a PCRII vector (Invitrogen, Calif., USA), and then the full-length nucleotide sequences were determined by the Dideoxy method. As a result, a 1454 bp DNA fragment amplified with the primer pair of C11A and C11C completely matched the c-erg gene (Mechanism of Development (1995) 50: 17-28), whereas a 1373 bp DNA fragment turned out to be a sequence lacking 81 bases of from nucleotide 655 to nucleotide 735, from the c-erg gene. This novel sequence thus obtained was designated “C-11”.

[0073] DNA fragments amplified using the primer pair of C11B and C11C were two kinds, namely 1446 bp and 1335 bp: the former fragment was c-erg and the latter was C-11. These results suggest the possibility that the thus obtained C-11 gene is an isoform of the c-erg gene.

[0074] It was also possible to isolate the aforementioned C-11 gene by a conventional subtraction method. Particularly, according to the subtraction method ordinarily known in the art, a cDNA which had specifically expressed in the embryonic sterna was cloned by employing a cDNA library of chicken embryonic sterna and fibroblasts. From the thus obtained candidate clones, genes were amplified by the PCR reaction using suitable primers to provide amplified gene products, the full nucleotide sequences of which were determined by standard techniques.

[0075] Results obtained with the aforementioned c-erg gene are shown through Example 2-1 to Example 2-8 as described below. In a like manner, experiments were conducted using the aforementioned C-11 gene and results therefrom are shown below, together with these for the c-erg gene.

EXAMPLE 2-1

[0076] Construction of a Vector Containing the c-erg Gene

[0077] The cloned c-erg as described above was subcloned into a RCAS vector (See, Journal of Virology (1987), Oct.: 3004-3012) at its ClaI site in sense (c-erg) and antisense (AS-c-erg) directions, respectively. That they were indeed sense and antisense as described was confirmed by DNA sequencing.

[0078] The RCAS vector containing the subcloned c-erg and that containing the subcloned AS-c-erg were, respectively, introduced into chicken embryonic fibroblasts by the calcium phosphate co-precipitation method as described in Chen C. and Okayama H., Mol. Cell Biol. (1987), 7: 2745-2752. The vector-introduced cells were cultured for 48 hours at 37° C. on a DMEM medium containing 10% fetal bovine serum (The Nikken Biological Science Research Institute, Kyoto). Subsequently, virus produced in the culture supernatant was concentrated by means of a ultrafiltration membrane (molecular weight: 30,000 cut) (Centriprep available from Amicon Inc., Mass., USA). This virus is herein referred to as “virus-CM”.

[0079] In a like manner, only the RCAS vector was introduced into chicken embryonic fibroblasts and the virus recovered from the vector-introduced cells was used as a control.

[0080] A virus stock from the aforementioned chicken embryonic fibroblasts which was used in this invention was prepared by the method as described below. Specifically, CEF was transfected with a DNA which had been obtained from RSV (Rous Sarcoma Virus) by substitution of its v-src with a target gene by means of Calcium phosphate method and which contained a proviral structure with LTR at its both ends. The cells into which the genes were introduced, temporarily released a large quantity of virus. Then, the virus reached the state of propagation throughout the whole culture used in the transfection by virus infection. At this point, a virus stock was recovered from the culture medium. More specifically, CEF cells propagated in a confluent manner, which had been cultured 4-5 days after preparation, were inoculated in a 60 mm dish at 0.8×10⁶ cells. On the following day, 10 μg of a DNA fragment or plasmid, each of which had been provided with a proviral structure, was introduced into the cells by transfection, according to the calcium phosphate co-precipitation method. The medium was made afresh one to two hours prior to transfection. Ten hours after transfection, the culture medium was washed three times with a standard medium and then the cells were allowed to propagate for two days. The whole culture transfected was passaged to a 90 mm dish and allowed to propagate for two additional days. The medium was made afresh and it was recovered as the virus stock after 48 hours. A new medium was again added to the culture medium and, after 12 hours, a virus stock was recovered for the second time.

EXAMPLE 2-2

[0081] Introduction of the c-erg Gene into Cells

[0082] The c-erg gene was introduced into chicken osteoblasts to observe the effects according to the method of Iwamoto et al. as described in J. Biol. Chem., (1993) 268(13): 9645-52. Parietal bones were excised from a chicken, 18 days old and osteoblasts for use were isolated from the bones by the method of Louis C. G. et al. as described in Developmental Biology (1987), 122: 49-60.

[0083] Virus-CM (and the control virus) prepared in Example 2-1 was added to the osteoblasts prepared as described above and virus infection was allowed to take place.

[0084] Whether or not the infection had occurred was determined by observing changes in the differentiation character of the cells. Infection efficiency toward virus cells was determined by staining the osteoblasts using a P19 antivirus antibody (Development Studies Hybridoma Bank) as described in Potts W. M. et al., J. Gen. Viol., (1982), 68: 3177-3182.

EXAMPLE 2-3

[0085] Morphological Observation of a Transformant with the c-erg Gene

[0086] The virus-infected osteoblasts obtained in Example 2-2 were observed under a phase contrast microscope with a magnification of 10. The result revealed that when compared with the cells in the control group, the virus-infected osteoblasts showed polygonal morphology in a smaller size (data not shown in the Drawings).

EXAMPLE 2-4

[0087] Detection of Expression of the c-erg Gene and C-11 Gene

[0088] To detect the expression of the aforementioned isoform, the C-11 gene, the RT-PCR method was performed according to the procedure as described below.

[0089] Total RNA was prepared from the pectus spinal tissue of chicken embryos, 18 days old by the method of Iwamoto et al. as described in Microscopy Research and Technique (1994), 28: 483-491. After converting this RNA into a DNA by means of a random hexamer and a superscript reverse transcriptase (both available from Gibco-BRL, MD, USA), the PCR amplification reaction was performed using Primers C11A and C11C (SEQ ID NO. 5 and SE ID NO. 7 set forth in the Sequence Listing) which had the nucleotide sequence for the ETA region (erg/ets transcription region) of the c-erg gene shown in FIG. 2, and that for the NRT region (transcription repressor region), respectively. In FIG. 2, the one that lacks 81 bases being flanked with the ETA and NRT domains is the C-11 gene. The thus obtained amplified products were subjected to electrophoresis on a 2% agarose gel and the results are shown in FIG. 3. These results revealed that the kinds of mRNA were amplified to show the isoform G11 gene as a 392 bp band together with the c-erg gene (as a 473 bp band).

EXAMPLE 2-5

[0090] Measurement of DNA Synthesizing Ability

[0091] The DNA synthesizing ability of the c-erg transformant cells was measured by the procedure described below.

[0092] After washing the cells with a cooled physiological saline solution three times, the cells were recovered from a physiological saline solution containing 0.01N NaOH and 0.2 v/v% Triton X-100. Upon recovery, the cells were crushed by ultrasonication and centrifuged to provide a supernatant which was used as a sample in the measurement. To 100 μl supernatant was added 200 μl of 0.1 g/ml DABA (3,5-diaminobenzoic acid dihydrochloride). After incubation for 45 minutes at 65° C. under a light-shielding condition, the reaction was terminated by adding 300 μl of 2N HCl. Upon termination of the reaction, fluorescence was monitored at wavelengths of 420 and 510 nm.

[0093] As used herein, “Rcas (or RCAS)” means the cells infected with the vector only. “c-erg-L14” means a RCAS into which a sense segment of the c-erg gene has been introduced. “c-erg-L44” means a RCAS into which an antisense segment of the c-erg gene has been introduced. Further, “C-11-L14” means a RCAS into which a sense segment of the C-11 gene has been introduced.

[0094] As shown in FIG. 4, it was found that either of c-erg-L14 and c-erg-L44 (into both of which c-erg had been introduced) showed no significant difference in the DNA synthesizing ability as compared with RCAS (into which c-erg had not been introduced). In contrast, as shown in FIG. 5, it was found that C-11-L14 (into which C-11 had been introduced) showed a significant increase in the DNA synthesizing ability as compared with RCAS itself. This increase was particularly noted until day 6.

EXAMPLE 2-6

[0095] Measurement of Alkaline Phosphatase Activity

[0096] The alkaline phosphatase activity was measured according to the method of Kato Y. et al. as described in Endocrimology (1990), 127: 114-118.

[0097] Specifically, after washing the cells on ice with a cooled physiological saline solution three times, the cells were recovered from a physiological saline solution containing 0.2 v/v % Triton X-100. Upon recovery, the cells were crushed by ultrasonication and centrifuged to provide a supernatant which was used as a sample in the measurement.

[0098] The alkaline phosphatase activity of the supernatant was measured in 0.5M Tris/HCl buffer (pH 9.0) containing 0.5 mM pNP (para-nitrophenyl phosphate) and 0.5 mM MgCl₂. After incubating the mixed solution for 30 minutes at 37° C., the reaction was terminated by adding 0.25 volume of 1N NaOH. Upon termination of the reaction, absorbance was monitored at a wavelength of 410 nm.

[0099] The results obtained employing RCAS, into which c-erg was introduced, are shown in FIG. 6. While no significant difference was observed between RCAS (which was the control) and c-erg-L44 (anti-sense segment introduced), the alkaline phosphatase activity of c-erg-L14 (sense-segment introduced) was found to be markedly inhibited.

[0100] Similarly, the results obtained employing C-11-L14, into which a sense segment of the C-11 gene was introduced, are shown in FIG. 7. As compared with RCAS which was the control, the alkaline phosphatase activity of C-11-L14 was found to be markedly inhibited.

EXAMPLE 2-7

[0101] Alizarin Red Staining

[0102] After washing the cultured osteoblasts (on day 12 after inoculation) with PBS (phosphate buffer saline) twice the cells were fixed with 100% ethanol. After fixation, Alizarin Red S (sodium alizarin sulfonate available from Wako Pure Chemicals) was dissolved in distilled water and adjusted to pH 6.3-6.4 with 0.1 N NH₃, yielding a 1% Alizarin solution. This was added to the cells to effect staining for two minutes. After staining, the cells were washed with distilled water and air-dried.

[0103] Following the abovementioned operations, the calcification sites of the cells were stained reddish orange.

[0104]FIG. 8 illustrates the results obtained by measuring the amount of deposition of calcified products in a culture system of the osteoblasts on day 19 after inoculation by means of Alizarin Red. Both uninfected cells and cells infected with the RCAS vector itself showed similar degrees of deposition of the calcified products. On the other hand, for c-erg-L14 (c-erg sense segment-introduced RCAS), the deposition was about half that for c-erg-L44 (c-erg anti-sense segment-introduced RCAS).

[0105] Further, FIG. 9 illustrates that in the case of a C-11-L14 RCAS into which a sense segment of C-11 was introduced, almost no deposition of the calcified products was observed as the result of measurement with Alizarin Red.

[0106]FIG. 10 illustrates the results from staining with Alizarin Red to compare the amounts of deposition of such calcified products. When compared under conditions where deposition of the calcified products was clearly observed in the cells infected with RCAS itself, c-erg L44 showed an extremely small inhibition on deposition of the calcified products. In contrast c-erg-L14 was found to nearly inhibit the deposition and C-11-L14 was found to almost completely inhibit the deposition.

EXAMPLE 2-8

[0107] von Kossa Staining

[0108] After washing the cultured osteoblasts (on day 12 after inoculation) with PBS twice, the cells were fixed with 100% ethanol. Then a 1% solution of silver nitrate was added to the cells and the solution was exposed to the sunlight for 30 minutes. Subsequently, the cells were washed with distilled water, to which a 5% aqueous solution of sodium thiosulfate was added. After allowing to stand for 5-10 minutes, the cells were washed with water. After washing, staining of cell nuclei was performed by adding an Alum-carmine solution and allowing to stand for 24 hours.

[0109] Following the abovementioned operations, the calcification'sites of the cells were stained black, while the nuclei were stained crimson.

[0110] As in the Alizarin Red staining, with application of the von Kossa staining a lowered staining was observed and the deposition of the calcified products was inhibited in the c-erg-L14 group as compared with the control group (RCAS). Further, in the C-11-L14 group, the deposition was completely inhibited. The staining with Alum-carmine showed no discrimination among various groups. Therefore, the observed effects in this invention are not ascribable to variations in staining efficiency resulting from differences in the cell number, but are believed to be due to the fact that both c-erg-L14 and C-11-L14 functionally inhibit the calcification of the osteoblasts (amount of calcium deposited per cell).

1 7 1 1447 DNA C-11 gene, c-erg gene w/ deletion, chicken DNA 1 gaattccgcg aacgaataat tattattagc aattattagc gatcaataat cttgatcaca 60 ttatggcaag cactattaag gaagcattat cagtggtgag tgaagaccag tccttgtttg 120 agtgtgccta cggatcgccc caccttgcaa agacagaaat gacagcctcc tcttccagtg 180 aatatgggca aacatcaaag atgagcccgc gcgttcccca gcaggactgg ttatcacagc 240 ccccggccag agttaccatt aagatggagt gtaacccaaa ccaggttaat gggtcaagga 300 attcacctga tgactgcagc gtggcaaaag gagggaaaat ggttagcagt tcagacaatg 360 ttgggatgaa ctatggaagc tacatggaag agaagcatat tccgcctcca aatatgacaa 420 ccaatgaacg aagagttatt gtgccagcag atcctacgtt atggagcaca gaccatgtac 480 ggcagtggct ggagtgggca gtgaaggagt atggtcttcc agacgtggac atcttgttgt 540 tccagaacat tgatgggaaa gagttgtgta aaatgaccaa agatgacttc cagagactca 600 cgccgagcta taacgcagat atcctcctgt cacacctaca ctacctcaga gagagaggag 660 ccacttttat ttttccaaat acatcagttt acccagaagc aacgcaaaga ataacaacaa 720 ggccagattt accttatgag caagcgagga gatcagcgtg gacgagtcac agccatccca 780 ctcagtcaaa agctacccaa ccatcatctt caacagtgcc caaaacagaa gaccagcgtc 840 ctcagttaga tccttatcag attcttggac cgaccagcag ccgtcttgca aatccaggga 900 gtgggcagat acagctatgg cagttcctac tggagcttct gtcggacagc tccaactcca 960 actgcatcac ctgggagggc acaaatgggg agttcaagat gacagaccct gatgaagtgg 1020 ctcggcgttg gggagagagg aaaagcaaac ctaacatgaa ctatgacaaa ctcagccgtg 1080 cacttcgcta ctactatgac aaaaatatta tgactaaagt tcatggtaaa cgctatgcct 1140 acaaatttga tttccacgga atcgctcagg ccctccagcc tcaccctcca gaatcatcca 1200 tgtacaaata cccatcagac ctcccctaca tgagttccta ccatgcacac ccccagaaga 1260 tgaactttgt agctccccat ccccctgctt tgcccgtaac ctcatccagc ttttttgctg 1320 cccctaatcc atactggaat tcaccaactg gaggcatcta ccccaatacc aggctgccag 1380 ctgctcatat gccttcccat cttggcacct actactaagt ggggaaagaa agaaagcgcc 1440 aagaaaa 1447 2 451 PRT protein sequence from C-11 gene 2 Met Ala Ser Thr Ile Lys Glu Ala Leu Ser Val Val Ser Glu Asp Gln 1 5 10 15 Ser Leu Phe Glu Cys Ala Tyr Gly Ser Pro His Leu Ala Lys Thr Glu 20 25 30 Met Thr Ala Ser Ser Ser Ser Glu Tyr Gly Gln Thr Ser Lys Met Ser 35 40 45 Pro Arg Val Pro Gln Gln Asp Trp Leu Ser Gln Pro Pro Ala Arg Val 50 55 60 Thr Ile Lys Met Glu Cys Asn Pro Asn Gln Val Asn Gly Ser Arg Asn 65 70 75 80 Ser Pro Asp Asp Cys Ser Val Ala Lys Gly Gly Lys Met Val Ser Ser 85 90 95 Ser Asp Asn Val Gly Met Asn Tyr Gly Ser Tyr Met Glu Glu Lys His 100 105 110 Ile Pro Pro Pro Asn Met Thr Thr Asn Glu Arg Arg Val Ile Val Pro 115 120 125 Ala Asp Pro Thr Leu Trp Ser Thr Asp His Val Arg Gln Trp Leu Glu 130 135 140 Trp Ala Val Lys Glu Tyr Gly Leu Pro Asp Val Asp Ile Leu Leu Phe 145 150 155 160 Gln Asn Ile Asp Gly Lys Glu Leu Cys Lys Met Thr Lys Asp Asp Phe 165 170 175 Gln Arg Leu Thr Pro Ser Tyr Asn Ala Asp Ile Leu Leu Ser His Leu 180 185 190 His Tyr Leu Arg Glu Arg Gly Ala Thr Phe Ile Phe Pro Asn Thr Ser 195 200 205 Val Tyr Pro Glu Ala Thr Gln Arg Ile Thr Thr Arg Pro Asp Leu Pro 210 215 220 Tyr Glu Gln Ala Arg Arg Ser Ala Trp Thr Ser His Ser His Pro Thr 225 230 235 240 Gln Ser Lys Ala Thr Gln Pro Ser Ser Ser Thr Val Pro Lys Thr Glu 245 250 255 Asp Gln Arg Pro Gln Leu Asp Pro Tyr Gln Ile Leu Gly Pro Thr Ser 260 265 270 Ser Arg Leu Ala Asn Pro Gly Ser Gly Gln Ile Gln Leu Trp Gln Phe 275 280 285 Leu Leu Glu Leu Leu Ser Asp Ser Ser Asn Ser Asn Cys Ile Thr Trp 290 295 300 Glu Gly Thr Asn Gly Glu Phe Lys Met Thr Asp Pro Asp Glu Val Ala 305 310 315 320 Arg Arg Trp Gly Glu Arg Lys Ser Lys Pro Asn Met Asn Tyr Asp Lys 325 330 335 Leu Ser Arg Ala Leu Arg Tyr Tyr Tyr Asp Lys Asn Ile Met Thr Lys 340 345 350 Val His Gly Lys Arg Tyr Ala Tyr Lys Phe Asp Phe His Gly Ile Ala 355 360 365 Gln Ala Leu Gln Pro His Pro Pro Glu Ser Ser Met Tyr Lys Tyr Pro 370 375 380 Ser Asp Leu Pro Tyr Met Ser Ser Tyr His Ala His Pro Gln Lys Met 385 390 395 400 Asn Phe Val Ala Pro His Pro Pro Ala Leu Pro Val Thr Ser Ser Ser 405 410 415 Phe Phe Ala Ala Pro Asn Pro Tyr Trp Asn Ser Pro Thr Gly Gly Ile 420 425 430 Tyr Pro Asn Thr Arg Leu Pro Ala Ala His Met Pro Ser His Leu Gly 435 440 445 Thr Tyr Tyr 450 3 1528 DNA c-erg gene, chicken DNA 3 gaattccgcg aacgaataat tattattagc aattattagc gatcaataat cttgatcaca 60 ttatggcaag cactattaag gaagcattat cagtggtgag tgaagaccag tccttgtttg 120 agtgtgccta cggatcgccc caccttgcaa agacagaaat gacagcctcc tcttccagtg 180 aatatgggca aacatcaaag atgagcccgc gcgttcccca gcaggactgg ttatcacagc 240 ccccggccag agttaccatt aagatggagt gtaacccaaa ccaggttaat gggtcaagga 300 attcacctga tgactgcagc gtggcaaaag gagggaaaat ggttagcagt tcagacaatg 360 ttgggatgaa ctatggaagc tacatggaag agaagcatat tccgcctcca aatatgacaa 420 ccaatgaacg aagagttatt gtgccagcag atcctacgtt atggagcaca gaccatgtac 480 ggcagtggct ggagtgggca gtgaaggagt atggtcttcc agacgtggac atcttgttgt 540 tccagaacat tgatgggaaa gagttgtgta aaatgaccaa agatgacttc cagagactca 600 cgccgagcta taacgcagat atcctcctgt cacacctaca ctacctcaga gagactcctc 660 ttccacattt gacttcagat gatgttgata aggccttaca aaactctcca cggttaatgc 720 atgctagaaa cacaggagga gccactttta tttttccaaa tacatcagtt tacccagaag 780 caacgcaaag aataacaaca aggccagatt taccttatga gcaagcgagg agatcagcgt 840 ggacgagtca cagccatccc actcagtcaa aagctaccca accatcatct tcaacagtgc 900 ccaaaacaga agaccagcgt cctcagttag atccttatca gattcttgga ccgaccagca 960 gccgtcttgc aaatccaggg agtgggcaga tacagctatg gcagttccta ctggagcttc 1020 tgtcggacag ctccaactcc aactgcatca cctgggaggg cacaaatggg gagttcaaga 1080 tgacagaccc tgatgaagtg gctcggcgtt ggggagagag gaaaagcaaa cctaacatga 1140 actatgacaa actcagccgt gcacttcgct actactatga caaaaatatt atgactaaag 1200 ttcatggtaa acgctatgcc tacaaatttg atttccacgg aatcgctcag gccctccagc 1260 ctcaccctcc agaatcatcc atgtacaaat acccatcaga cctcccctac atgagttcct 1320 accatgcaca cccccagaag atgaactttg tagctcccca tccccctgct ttgcccgtaa 1380 cctcatccag cttttttgct gcccctaatc catactggaa ttcaccaact ggaggcatct 1440 accccaatac caggctgcca gctgctcata tgccttccca tcttggcacc tactactaag 1500 tggggaaaga aagaaagcgc caagaaaa 1528 4 478 PRT protein sequence from c-erg gene 4 Met Ala Ser Thr Ile Lys Glu Ala Leu Ser Val Val Ser Glu Asp Gln 1 5 10 15 Ser Leu Phe Glu Cys Ala Tyr Gly Ser Pro His Leu Ala Lys Thr Glu 20 25 30 Met Thr Ala Ser Ser Ser Ser Glu Tyr Gly Gln Thr Ser Lys Met Ser 35 40 45 Pro Arg Val Pro Gln Gln Asp Trp Leu Ser Gln Pro Pro Ala Arg Val 50 55 60 Thr Ile Lys Met Glu Cys Asn Pro Asn Gln Val Asn Gly Ser Arg Asn 65 70 75 80 Ser Pro Asp Asp Cys Ser Val Ala Lys Gly Gly Lys Met Val Ser Ser 85 90 95 Ser Asp Asn Val Gly Met Asn Tyr Gly Ser Tyr Met Glu Glu Lys His 100 105 110 Ile Pro Pro Pro Asn Met Thr Thr Asn Glu Arg Arg Val Ile Val Pro 115 120 125 Ala Asp Pro Thr Leu Trp Ser Thr Asp His Val Arg Gln Trp Leu Glu 130 135 140 Trp Ala Val Lys Glu Tyr Gly Leu Pro Asp Val Asp Ile Leu Leu Phe 145 150 155 160 Gln Asn Ile Asp Gly Lys Glu Leu Cys Lys Met Thr Lys Asp Asp Phe 165 170 175 Gln Arg Leu Thr Pro Ser Tyr Asn Ala Asp Ile Leu Leu Ser His Leu 180 185 190 His Tyr Leu Arg Glu Thr Pro Leu Pro His Leu Thr Ser Asp Asp Val 195 200 205 Asp Lys Ala Leu Gln Asn Ser Pro Arg Leu Met His Ala Arg Asn Thr 210 215 220 Gly Gly Ala Thr Phe Ile Phe Pro Asn Thr Ser Val Tyr Pro Glu Ala 225 230 235 240 Thr Gln Arg Ile Thr Thr Arg Pro Asp Leu Pro Tyr Glu Gln Ala Arg 245 250 255 Arg Ser Ala Trp Thr Ser His Ser His Pro Thr Gln Ser Lys Ala Thr 260 265 270 Gln Pro Ser Ser Ser Thr Val Pro Lys Thr Glu Asp Gln Arg Pro Gln 275 280 285 Leu Asp Pro Tyr Gln Ile Leu Gly Pro Thr Ser Ser Arg Leu Ala Asn 290 295 300 Pro Gly Ser Gly Gln Ile Gln Leu Trp Gln Phe Leu Leu Glu Leu Leu 305 310 315 320 Ser Asp Ser Ser Asn Ser Asn Cys Ile Thr Trp Glu Gly Thr Asn Gly 325 330 335 Glu Phe Lys Met Thr Asp Pro Asp Glu Val Ala Arg Arg Trp Gly Glu 340 345 350 Arg Lys Ser Lys Pro Asn Met Asn Tyr Asp Lys Leu Ser Arg Ala Leu 355 360 365 Arg Tyr Tyr Tyr Asp Lys Asn Ile Met Thr Lys Val His Pro Pro Glu 370 375 380 Ser Ser Met Tyr Lys Tyr Pro Ser Asp Leu Pro Tyr Met Ser Ser Tyr 385 390 395 400 His Gly Lys Arg Tyr Ala Tyr Lys Phe Asp Phe His Gly Ile Ala Gln 405 410 415 Ala Leu Gln Pro His Ala His Pro Gln Lys Met Asn Phe Val Ala Pro 420 425 430 His Pro Pro Ala Leu Pro Val Thr Ser Ser Ser Phe Phe Ala Ala Pro 435 440 445 Asn Pro Tyr Trp Asn Ser Pro Thr Gly Gly Ile Tyr Pro Asn Thr Arg 450 455 460 Leu Pro Ala Ala His Met Pro Ser His Leu Gly Thr Tyr Tyr 465 470 475 5 23 DNA primer for isolation of C-11 and c-erg genes 5 atcttgatca cattatggca agc 23 6 25 DNA primer for isolation of C-11 and c-erg genes 6 cacattatgg caagcactat taagg 25 7 25 DNA primer for isolation of C-11 and c-erg genes 7 cacttagtag taggtgccaa gatgg 25 

What is claimed is:
 1. A C-11 protein comprising a protein selected from the group consisting of: (a) a protein comprising an amino acid sequence having SEQ ID NO. 2 (SEQUENCE LISTING); and (b) a protein comprising an amino acid sequence that is derived from the amino acid sequence having SEQ ID NO. 2 by deletion, substitution or insertion of one or more amino acids, said protein having cell-calcification inhibitory activity.
 2. A gene encoding the protein according to claim
 1. 3. A pharmaceutical composition comprising the protein according to claim
 1. 4. The pharmaceutical composition according to claim 3, wherein said composition is intended for a cell-calcification inhibitor.
 5. A cell-calcification inhibitor comprising a c-erg protein selected from the group consisting of: (a) a protein comprising an amino acid sequence having SEQ ID NO. 4 (SEQUENCE LISTING); and (b) a protein comprising an amino acid sequence that is derived from the amino acid sequence having SEQ ID NO. 4 by deletion, substitution or insertion of one or more amino acids, said protein having cell-calcification inhibitory activity.
 6. An antibody to the C-11 protein according to claim
 1. 7. The antibody according to claim 6, wherein said antibody is a monoclonal antibody.
 8. A method for measuring the calcification of cells comprising: measuring the expression of a C-11 gene or a c-erg gene in the cells.
 9. The method according to claim 8, wherein the expression of the gene is measured by the amount of C-11 mRNA expressed in the cells or the amount of c-erg mRNA expressed in the cells using a probe against a DNA sequence specific to the C-11 gene or to the c-erg gene.
 10. The method according to claim 8, wherein the expression of the gene is measured by the amount of expression of a C-11 protein in the cells or the amount of expression of a c-erg protein in the cells.
 11. The method according to claim 8, wherein the expression of the gene is measured by the amount of the C-11 protein expressed in the cells or the amount of the c-erg protein expressed in the cells by means of the antibody according to claims 6, or
 7. 12. A method for diagnosing osteoarthritis or OPLL comprising: measuring the cell-calcification using a method according to any of claims 8-11.
 13. A kit for measuring the cell-calcification of cells comprising either or both of an antibody to a C-11 protein and an antibody to a c-erg protein.
 14. A method for screening a substance having cell-calcification inhibitory blocking activity, said method comprising using cells transformed with a gene encoding a protein selected from the group consisting of: (a) a protein comprising an amino acid sequence having SEQ ID NO. 2 (SEQUENCE LISTING); (b) a protein comprising an amino acid sequence that is derived from the amino acid sequence having SEQ ID NO. 2 by deletion, substitution or insertion of one or more amino acids, said protein having cell-calcification inhibitory activity; (c) a protein comprising an amino acid sequence having SEQ ID NO.
 4. (SEQUENCE LISTING); and (d) a protein comprising an amino acid sequence that is derived from the amino acid sequence having SEQ ID NO. 4 by deletion, substitution or insertion of one or more amino acids, said protein having cell-calcification inhibitory activity.
 15. A pharmaceutical composition comprising an erg protein.
 16. A pharmaceutical composition comprising an erg gene.
 17. A pharmaceutical composition comprising a C-11 protein or a c-erg protein.
 18. A pharmaceutical composition comprising a C-11 gene or a c-erg gene.
 19. A pharmaceutical composition comprising a protein having a consensus amino acid sequence between a c-erg protein and a C-11 protein. 